The Claim
An average LDL treatment-year exposure above 135.6 is associated with a significant reduction in major adverse cardiovascular events, while an exposure below 57.8 is not, indicating that the magnitude and duration of LDL lowering jointly determine clinical benefit.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People treated with LDL-lowering therapies for longer durations and at higher cumulative levels have fewer heart attacks and strokes compared to those with lower cumulative exposure.
See the scientific wording
Trials that achieved an average LDL treatment-year exposure above 135.6 showed a significant reduction in major adverse cardiovascular events, while those below 57.8 did not, suggesting that the magnitude and duration of LDL lowering jointly determine clinical benefit.
Lowering LDL cholesterol over time reduces the buildup of fatty deposits in artery walls, stops those deposits from becoming unstable, and decreases inflammation in the blood vessel lining, which prevents clots from forming and blocking blood flow.
What the research says
1 studyStudy: LDL treatment-years: a new paradigm for cardiovascular risk reduction
This study found that people who took cholesterol-lowering drugs at higher doses for longer periods had fewer heart attacks and strokes — especially when their total exposure reached about 136 LDL treatment-years. Those with lower exposure didn’t see the same benefit.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.